Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's AZD-2693?
AZD-2693 is an antisense oligonucleotide commercialized by AstraZeneca, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH). According...
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's AZD-2693?
AZD-2693 is an antisense oligonucleotide commercialized by AstraZeneca, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH). According...